Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
VALTREX (valacyclovir) is an oral antiviral small molecule that inhibits α-herpes viruses by blocking viral DNA replication. It treats cold sores, genital herpes, shingles, and chickenpox in immunocompetent populations across pediatric and adult age groups. The drug is indicated for both acute episodes and transmission prevention.
Mature product approaching loss of exclusivity with minimal Part D utilization; expect team rationalization and transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)
Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
Worked on VALTREX at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moVALTREX has zero linked job openings and minimal career visibility on the job market. Working on this product primarily involves managing decline, defending market share against generics, and cost containment rather than growth initiatives.